Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized anti-GD2 immunotherapy trial in high-risk neuroblastoma
NL-OMON44066Phase 2Withdrawn
- Sponsor
- SKion
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dinutuximab, aldesleukin, sargramostim and tretinoin in neuroblastoma (2 arms), sponsored by SKion. Primary endpoints: Safety and Tolerability. Planned start Feb 2016; status: withdrawn.
02
Drugs
dinutuximabaldesleukinsargramostimtretinoin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON44066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44066.